Cetuximab (Erbitux) is an anti-epidermal growth factor receptor (EGFR) monoclonal antibody whose activity is related to the inhibition of EGFR downstream signaling pathways. P53 and phosphatase and tensin homologue deleted on chromosome 10 (PTEN) have been reported to control the functionality of PI3K/AKT signaling. In this study we evaluated whether reintroducing P53 using non-viral gene transfer enhances PTEN-mediated inhibition of PI3K/AKT signaling by cetuximab in PC3 prostate adenocarcinoma cell line bearing p53 and pten mutations. Signaling phosphoproteins expression was analyzed using Bio-Plex phosphoprotein array and western blot. Apoptosis induction was evaluated from BAX expression, caspase-3 activation and DNA fragmentation analyses. The results presented show that p53 and pten gene transfer additionally mediated cell growth inhibition and apoptosis induction by restoral of signaling functionality, which enabled the control of PI3K/AKT and MAPKinase signaling pathways by cetuximab in PC3 cells. These results highlight the interest of the analysis of signaling phosphoproteins expression as molecular predictive markers for response to cetuximab and show that p53 and pten mutations could be key determinants of cell response to cetuximab through the functional impact of these mutations on cell signaling.
Introduction
The high frequency of overexpression of epidermal growth factor receptor (EGFR) in various cancers 1 and its major function in tumorigenesis have suggested that inhibition of EGFR stimulation and inhibition of downstream signaling pathways could represent new therapeutic approaches in cancer treatment and have opened the way of targeted therapies. Different concepts have been proposed for inhibition of EGFR activation including monoclonal antibodies and tyrosine kinase inhibitors. Cetuximab is a chimeric monoclonal antibody developed for therapeutic purposes, which binds to EGFR with high affinity and abrogates ligand-induced EGFR phosphorylation. 2 In preclinical models, EGFR inhibition by monoclonal antibody or by the use of tyrosine kinase inhibitors has been associated with decreased cell proliferation, increased apoptosis and decreased angiogenesis. [3] [4] [5] However, a large number of patients whose tumors overexpress EGFR do not respond to targeted therapy. 6, 7 In prostate cancer, frequent gene mutations concern the p53 and phosphatase and tensin homologue deleted on chromosome 10 (pten) tumor suppressor genes. P53 is a transcription factor that regulates the cell-cycle arrest, DNA repair and apoptosis. In fact, p53 is probably the most frequently mutated gene in human cancer. Loss of p53 contributes to tumor progression, therapeutic resistance and is often associated with a poor prognosis. The rate of mutations in prostate cancer in the p53 tumor suppressor gene varied among tumors of different aggressiveness, ranging from 5% for patients with clinically localized disease to 62% in metastatic disease. 8 P53 may also affect the signaling pathways that are involved in cell growth and transformation. P53 reintroduction has been shown to significantly produce greater apoptosis and tumor growth suppression than any other drug alone. 9 Recent data showed that sensitivity to gefitinib is affected by P53 mutation and that P53 inhibition induces a significant decrease in apoptosis induction by gefitinib. 10 Previous study already demonstrated that cetuximab inhibited the growth of wild-type p53 but not of mutated p53 cancer cells and hypothesized that resistance to cetuximab could relate to p53 mutation. 11 In addition, recent study showed that induction of P53 resulted in decreased in phosphorylated AKT activity in cell line, which did not express PTEN protein, thus highlighting that p53 was involved in regulation of survival PI3K/AKT pathway in epithelial tumors, and independently of PTEN expression. 12 It was reported that activation of p53-dependent downstream targets BAX with concomitant increase of MAPKinase (MAPK) pathways leading to apoptosis. 13 Altogether, these data indicated that the relationship between P53, PI3K/AKT and MAPK signaling pathways offers novel valuable insights into the resistance to targeted therapy.
Pten was identified in 1997 as tumor suppressor 14 and alteration of pten gene has been shown to promote prostate cancer progression. 15 PTEN antagonizes the action of PI3K and negatively controls the downstream pathway by inhibiting the phosphorylation of AKT. 16 Consequently, the loss of PTEN expression leads to an elevated activation of AKT. 17 A recent study investigating protein expression demonstrated that PTEN has a fundamental function in predicting the response to cetuximab against EGFR in metastatic colorectal cancer. 18 A previous study showed that loss of PTEN expression was associated with resistance to gefitinib, and that reintroduction of PTEN restored cell sensitivity of gefitinib, thus suggesting that signaling pathway may have a central function in the development of resistance to EGFR inhibitors. 19 In the present study, we used PC3 human prostate carcinoma cell line harboring P53 and PTEN mutations. Our investigation was designed to evaluate whether p53 transfer could enhance PTENmediated growth inhibition and apoptosis induction to investigate the implication of PI3K/AKT and MAPK signaling proteins in response to cetuximab.
Materials and methods
Cell lines PC3 cell line was obtained from the American Type Culture Collection. The cells were cultured at 37 1C/5% CO 2 in RPMI 1640, supplemented with 10% heat inactivated fetal calf serum (Dutscher, Brumath, France) and 1% glutamine. Culture media and additives were from Life Technologies (Eragny, France).
Gene transfer
Linear polyethylenimine (PEI) was kindly provided by Polyplus-transfection (Illkirch, France). pCMV-Luc (Dr P Erbacher, Polyplus-transfection), pNCNeo (Dr JM Heard, Institut Pasteur, Paris, France) and pPTEN (Dr K Yamada, NIH, Bethesda, MD) plasmids, encoding luciferase, p53 and pten genes, respectively, were purified from Escherichia coli using Marligen maxiprep columns (Life Technologies).
Gene transfer was performed as already published 20 with slight modifications. Briefly, the cells were seeded at the density of 5 Â 10 4 ml À1 in six-well plates 48 h before transfection to reach 60-70% confluence at the time of transfection. pCMV-Luc or pNCNeo or pPTEN plasmids (5 mg ml À1 ) and corresponding amount of PEI were separately prepared and the resulting mixture was added to the cells. Twenty-four hours after transfection cells were submitted to 100 mg ml À1 cetuximab (Merck Lipha Sante, Lyon, France) and analyzed for cytotoxicity and apoptotic induction. Pten and p53 co-transfer was achieved using 2.5 mg ml À1 of each plasmid.
mRNA expression analysis
Pten-mRNA and p53-mRNA expression was analyzed using semiquantitative RT-PCR with b2-microglobulin (b2M1) as reference housekeeping gene as already reported.
20,21
Western blot Cells were exposed to epidermal growth factor (EGF, 100 ng ml À1 ) for 5 min (Roche Diagnostics, Penzberg, Germany). Western blots were carried out with total protein extracted from cells as already described using monoclonal antibody directed against PTEN, pPTEN, P53, AKT, phosphorylated-AKT (pAKT), GSK3b, pGSK3b, P70S6K, pP70S6K, ERK1/2, pERK1/2, BAX and tubulin 22 (Table 1) . Antibodies were used between were fixed 10 min in 96% ethanol. Immunocytochemistry was then performed after digestion in 10 mmol l À1 citrate buffer (pH 6), before exposure to the primary antibody. Briefly, the slides were treated by hydrogen peroxide, then incubated overnight at 4 1C with monoclonal antibodies against either PTEN (1:100 dilution), P53 (1:100 dilution) or EGFR (1:100 dilution) (Dako). Cells were then stained with biotinylated immunoglobulin secondary antibody according to the manufacturer's recommendations, revealed using LSAB kit (Dako). The slides were counterstained with hematoxylin. Negative control slides, without primary antibody, were examined for each staining.
Bio-Plex phosphoprotein array
Phosphoproteins were analyzed using Bio-Plex phosphoprotein array (Bio-Rad, Hercules, CA) based on multiplex sandwich bead immunoassays. Cells were exposed to EGF (100 ng ml
À1
) for 5 min. Phosphoprotein determination kits (Bio-Rad) were used according to the manufacturer's recommendations. Briefly, protein extracts were transferred into 96-well dishes and diluted with 25 ml buffered solution. Fluorescent capturing beads coupled to antibodies directed against the phosphoproteins (phospho-AKT, phospho-GSK3b, phospho-P70S6K, phospho-ERK1/2) were mixed, and added into each well and incubated overnight. Following incubation, the plates were washed and incubated with biotinylated antibodies fixing each target protein. Streptavidin-phycoerythrin solution was then added. The analysis consisted in a double laser fluorescence detection allowing simultaneous identification of the target protein through the red fluorescence emission signal of the bead and quantification of the target protein through the fluorescence intensity of phycoerythrin. Results were recorded as mean fluorescence intensities and compared to negative controls. Positive controls consisting in standard protein extract from cell lines were added to each series.
Cytotoxicity assay
Cytotoxicity assays were performed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). Briefly, the cells were seeded in 24-well dishes and allowed to grow for 48 h before being transfected with pten/PEI or p53/PEI complexes. Cells were then treated with cetuximab for 24 h. All incubations were terminated by adding 250 ml of MTT in each well. The reaction was allowed to proceed for 3 h at 37 1C. The formazan crystals were dissolved by adding 250 ml of sodium dodecylsulfate, and the absorbance was measured at 540 nm (Multiskan Ascent LabSystem).
Apoptosis induction DNA fragmentation apoptosis induction was analyzed by flow cytometry (FACSCalibur; Becton Dickinson, Le Pont de Claix, France) using propidium iodide labeling. Evidence of apoptotic cells was determined by the induction of DNA fragmentation (sub-G 1 peak). Briefly, cetuximab-treated cells were trypsinized, washed with phosphate-buffered saline (PBS), fixed in 70% ethanol for 30 min at 4 1C and suspended in PBS containing propidium iodide (1 mg ml
À1
) and RNase A (20 mg ml
). Fixed cells were subjected to flow cytometry.
Active caspase-3 expression Cells were washed with cold PBS and fixed in Cytofix/ Cytoperm (Becton Dickinson). Then, cells were incubated with phycoerythrin-conjugated anti-active caspase-3 antibodies (PharMingen-Becton Dickinson) for 30 min. Cells were washed and 500 ml of 1 Â Perm/Wash was added before analysis by flow cytometry.
Statistical analysis
Differences between mean values were evaluated using either one-way analysis of variance with Dunnett's test or Kruskal-Wallis with Mann-Whitney test according to data distribution. Pp0.05 was regarded as statistically significant.
Results

EGFR, PTEN and P53 expression
The immunocytochemistry analysis of PC3 cells (Figure 1) showed that PC3 cells overexpress EGFR with intense staining of more than 90% of the cell population and did not express P53 and PTEN proteins. Signaling Untransfected control PC3 cells were found to constitutively overexpress pAKT in relation with pten-null phenotype (Figure 3a) . Consequently, overexpression of downstream signaling phosphoproteins (pGSK3b and pP70S6K) was evidenced (Figure 3a) . Overexpression of phosphorylated-ERK1/2 (pERK1/2) was also observed (Figure 3a) . In negative control experiment, consisting in transfecting PC3 cells with irrelevant plasmid (pCMV-Luc), no difference in expression of phosphoproteins was found between PC3-transfected cells exposed or not to cetuximab and untransfected control cells exposed or not to cetuximab (data not shown).
As a whole, as well as protein by protein, all data obtained from Bio-Plex phosphoprotein array analysis were found to correlate with data calculated from numerized western blot (Po0.001). Therefore, all following considerations were calculated from Bio-Plex phosphoprotein array analyses.
Exposure of the untransfected cells to cetuximab led to a significant (Po0.001) major (98%) decrease in pEGFR expression (Figure 3a) . Although it did not induce any significant (P40.05) decrease of pAKT and pGSK3b expression, pP70S6K expression was significantly (Po0.05) reduced by 33%. pERK1/2 expression was also significantly (Po0.01) reduced by 54% (Figure 3a) .
In p53-transfected cells (Figure 3a) , inhibition of AKT signaling was observed with significant (Po0.05) reduction of pAKT expression by 40%, pGSK3b by 72% and pP70S6K by 35%. In addition, significant (Po0.01) decrease in pERK1/2 by 53% was observed. Exposure of p53-transfected cells to cetuximab further decreased the expression of all phosphoproteins.
In pten-transfected cells (Figure 3b ), unexposed to cetuximab, no inhibition of pEGFR expression was observed, whereas inhibition of AKT signaling was found to be restored with significant (Po0.01) reduction of pAKT expression by 63%, pGSK3b by 38% and pP70S6K by 45% (Figure 3 ). In addition, significant (Po0.01) decrease in pERK1/2 by 27% was observed. Exposure of pten-transfected cells to cetuximab led to near-complete abrogation of pEGFR expression (95%) and further significantly (Po0.05) decreased the expression of all phosphoproteins.
In pten/p53-cotransfected cells (Figure 3c ), similar results, that is, near-complete abrogation of pEGFR expression as well as AKT and ERK1/2 signaling inhibition, were achieved consistently with the data obtained in pten-or p53-transfected cells. Considering all experimental data achieved in PC3 cells using Bio-Plex phosphoprotein array, statistically significant correlations were found between pAKT expression and pGSK3b and pP70S6K expression (r ¼ 0.816, Po0.05 and r ¼ 0.859, Po0.01, respectively) ( Figure 4) . No correlation was found between pAKT and pERK1/2 expression (P40.05) (data not shown). Because the results observed with the co-transfer of pten and p53 genes were achieved with a 50:50 mixture of the plasmids and provided the same extent of inhibition of signaling, the combined effect was considered at least as additive.
In all experimental conditions, data achieved from immunocytochemistry (for EGFR only, data not shown) and numerized of western blots analyses revealed that no significant reduction of total protein expression was observed.
Growth inhibition and apoptosis induction
Negative controls, consisting in untransfected cells and cells transfected with irrelevant plasmid (pCMV-Luc), P53, PTEN and cetuximab sensitivity S Bouali et al Figure 3 Analysis epidermal growth factor receptor (EGFR) phosphorylation and AKT and MAPK signaling pathways functionality using Bio-Plex phosphoprotein array and western blotting analysis. Effect of p53 (a), pten (b), pten/p53 (c) restoration and exposure to cetuximab on AKT and MAPK signaling pathways. In each gene transfer condition, pEGFR, pAKT, pGSK3b, pP70S6K and pERK1/2 expression was analyzed using Bio-Plex phosphoprotein array (upper panels) and by western blotting (lower panels) on total cell lysates. Western blotting membrane was probed with specific antibodies raised against each protein and the corresponding phosphoprotein. Tubulin was probed with the specific antibodies as loading control.
P53, PTEN and cetuximab sensitivity
S Bouali et al then p53-, pten-and p53/pten-transfected PC3 cells were exposed to cetuximab (100 mg ml À1 for 24 h) and assayed for cytotoxicity using MTT assays. Apoptosis induction was determined using flow cytometry determination of sub-G 1 cells, active caspase-3 expression and BAX expression using western blot.
In negative controls ( Figure 5 ), no significant cytotoxicity of cetuximab was observed. This lack of cytotoxicity was associated with no significant apoptosis induction.
In p53-transfected cells ( Figure 5 ), this lack of cytotoxicity was found to be associated with significant (Po0.01) moderate cell cytotoxicity (20%; Figure 5a ) with spontaneous apoptosis induction (16% sub-G 1 ; Figure 5b ) consistent with increased caspase-3-expressing cell fraction (12%; Figure 5c ) and BAX expression (Figure 5d ). P53 gene transfer was found to significantly (Po0.01) sensitize PC3 cells to cetuximab with 37% increase in cell cytotoxicity, increase in sub-G 1 cell fraction (up to 21%). No subsequent increase in caspase-3-expressing cell fraction (10%) and BAX expression was evidenced. Pten gene transfer ( Figure 5 ), PTEN protein expression led to a significant (Po0.01) decrease (35%) in cell growth (Figure 5a ) and in consequence a significant (Po0.05) increase in cell apoptosis (11% sub-G 1 (Figure 5b ), 6% caspase-3-expressing cell fraction ( Figure 5c ) consistent with increased BAX expression (Figure 5d) ). Pten gene transfer was found to (Po0.01) sensitize significantly PC3 cells to cetuximab as a 30% increase in cytotoxicity, with increased apoptosis induction (22.5% sub-G 1 ), which was not found to be associated with subsequent significant increase in caspase-3-expressing cell fraction (8%) and increase in BAX expression.
P53/pten co-transfer ( Figure 5 ) yielded significant (Po0.05) further increase in cytotoxicity (35%; (Figure 5a) ) as compared to results achieved with either pten or p53 gene transfer alone. Apoptosis induction was significantly (Po0.01) increased as compared to pten gene transfer alone (18% sub-G 1 (Figure 5b ), 15% caspase-3-expressing cell fraction (Figure 5c ) and increased BAX expression (Figure 5d) ). No significant variation in apoptosis induction was evidenced between p53-and pten/p53-transfected cells. P53/pten gene transfer was found to potentiate cetuximab activity with significant (Po0.01) increase in cytotoxicity (40%) as compared to results achieved in either pten-or p53-transfected cells. Whatever the technique, apoptosis induction results were found to be fully consistent (25% sub-G 1 , 20% caspase-3-expressing cell fraction and increased BAX expression).
These data confirm that loss of P53 or/and PTEN in PC3 cell accounts for their resistance to cetuximab and that restoration of P53 or/and PTEN function can reestablished sensitivity to cetuximab. As in the signaling analyses, because the results observed with the co-transfer of pten and p53 genes were achieved with a 50:50 mixture of the plasmids and provided the same extent of cell growth inhibition and apoptosis induction, the combined effect was considered at least as additive.
Signaling phosphoproteins expression and cellular sensitivity to cetuximab As illustrated by cytotoxicity assays (Figure 6a) as well as by sub-G 1 apoptosis induction assays (Figure 6b) , cell response to cetuximab was found to correlate significantly with pAKT, pGSK3b, pP70S6K and pERK1/2 expression.
Comparison between western blot and Bio-Plex phosphoprotein array methods We observed an agreement between results in the Bio-Plex phosphoprotein array and the western blot using Bland-Altman plot analysis as shown in Figure 7 . The Passing-Bablok regression analysis showed a statistically significant correlation between the two methods ( Figure 7 ).
Discussion
The present study was performed in PC3 human prostate cancer cell line, which is referenced as p53 null because of a single base deletion in codon 138 that prevents its P53, PTEN and cetuximab sensitivity S Bouali et al expression 23 and leads to resistance to apoptosis and many chemotherapeutic agents.
In addition, PC3 cells are pten null because of a deletion of the 3 0 end of pten gene and promoting the absence of the full-length pten m-RNA. 24 Consistently, pten mutated status is associated with constitutive activation of AKT in PC3 cells and the constitutive high level of expression of pAKT causes a reduced sensitivity of PC3 cells to cetuximab. No mutation of PI3K has been reported in PC3 cells. The data achieved in the present study are fully consistent with these findings as PC3 cells were found to be resistant to apoptosis induced by cetuximab. 25 Our hypothesis was that reintroducing P53 in PC3 cells would enhance PTEN-mediated cetuximab-induced cell growth inhibition, by restoring EGFR downstream signaling pathways functionality and apoptosis induction. Introduction of p53 expression resulted in a significant increase in growth inhibition and apoptosis induction, thus confirming the well-established essential function of P53 as mediator of cell growth and apoptosis control already reported in the literature with p53 gene transfer in head and neck, and pancreatic cancer cell lines. 26, 27 These results are in agreement with a previous study, 11 which demonstrated that, in PTEN-deficient cells, p53 regulates cell survival by transcriptional downregulation of PIK3-CA (encoding p110 catalytic subunit of PI3K) independently of PTEN. Conversely, in pten intact cells, induction of p53 downregulates PIK3CA and increases PTEN protein expression 12 through a p53 response element located into PIK3CA promoter. These data were recently further confirmed as p53 was shown 28 to bind directly PIK3CA promoter and inhibit its activity with consequent alteration of many cellular functions.
When p53 gene transfer was combined with cetuximab, significant additive effects on growth inhibition, increased apoptosis induction and restoration of inhibition of pAKT and pERK1/2 expression were observed. These results are consistent with previous data, 11 hypothesizing that p53-mutated status may be implicated in cell resistance to cetuximab.
As awaited, reinstating PTEN in PC3 cells inhibited AKT activity and its downstream signaling pathways, and in consequence, an inhibition of cell growth and induction of apoptosis, confirming the importance of PTEN in the control of the cell survival pathway. These results are consistent with the now well-established model in which PTEN was shown to be essential for controlling cell growth in prostate human cancer cell lines 29 by regulating PI3K/AKT signaling pathways by decreasing the pool of phosphorylated proteins.
Many studies demonstrated that pAKT overexpression is associated with resistance to EGFR inhibitors. 19 Further, Li et al. 25 showed that resistance to cetuximab was associated with pAKT overexpression and inhibition of pAKT by siRNA AKT restored cetuximab sensitivity. Accordingly, we showed here that PTEN reintroduction restores the cytotoxicity of cetuximab by restoring inhibition of pAKT and pERK1/2. Therefore, these data further confirmed that PI3K/AKT and MAPK signaling pathways functionality contribute to cetuximab activity.
The present experiments demonstrated that, in addition to PTEN, the activity of cetuximab also greatly depends on P53 functionality. This is consistent with data already reporting that P53 expression is decreased in PTENÀ/À cells 30 through the increase of MDM2 activation caused by overexpression of pAKT. In addition to its influence on PI3K activity and consequent inhibition of AKT signaling, P53 could further influence the cell response to P53, PTEN and cetuximab sensitivity S Bouali et al cetuximab through its potential consequence onto PDK1. Furthermore, PDK1-mediated activation of NF-kB signaling pathways was shown to occur through direct IKKB phosphorylation independently to AKT signaling pathways. 31 In such context, the relationship between p53 and PI3K and between PTEN and PI3K demonstrated here that inhibition of PI3K could avoid the 'cross-talk' between PI3K downstream signaling pathways such as AKT and IKK/NF-kB signaling pathways. These data further suggest that PI3K could be a promising and attractive target for cancer therapy in patients harboring PTEN and/or P53 mutations with upregulation AKT signaling pathways.
In summary, these results strongly suggest that p53-and pten-mutated status could be predictive of resistance to cetuximab and warrant clinical evaluation to evaluate whether patients with p53-mutated tumors are unlikely to respond to this treatment as already shown with pten 18 and ras mutation 32 in colorectal cancer treated by cetuximab. Functional diagnostic criteria could be the determination of signaling phosphoprotein expression in tumors. 33 Preliminary results achieved in breast 34 and head and neck 35 and colon 36 tumors using Bio-Plex phosphoprotein array demonstrated that large variation in phosphoprotein expression can be found in clinical specimens at diagnosis and may contribute to variation in response to targeted therapy. In colon cancer, 36 our results demonstrated that signaling defects in K-Ras nonmutated tumors could additionally serve to predict progression-free survival. In the case of signaling alteration, combination of therapeutics targeting different signaling proteins can be proposed to circumvent this potential mechanism of resistance and obtain greater antitumor activity. Also, gene therapy could be envisaged in tumors with genes alteration, as already proposed for p53 using viral vector. 37 
Figure 6
Correlation between phosphoproteins expression and cytotoxicity (a), apoptosis (b) induction in PC3 cells. Phosphoproteins expression was quantified using Bio-Plex phosphoprotein array.
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